Improved voltage unbalance and harmonics compensation control strategy for an isolated microgrid

This paper suggests an enhanced control scheme for a four-leg battery energy storage systems (BESS) under unbalanced and nonlinear load conditions operating in the isolated microgrid. Simplicity, tiny steady-state error, fast transient response, and low total harmonic distortion (THD) are the main advantages of the method. Firstly, a new decoupled per-phase model for the three-phase four-leg inverter is presented. It can eliminate the effect of power stage coupling on control design; thus, the three-phase four-leg power inverter can be viewed as three single input single output (SISO) control systems. Then, using an improved orthogonal signal generation method, the per-phase model of the four-leg inverter in the stationary and synchronous frame is derived. As the second step, a per-phase multi-loop control scheme for the four-leg inverter under unbalanced load conditions is suggested. The proposed control strategy has the ability to provide balanced output voltages under unbalanced load conditions by avoiding the need to deal with the symmetrical components. Finally, a multi-resonant harmonic compensator is used to actively prevent low-order harmonic currents to distort the output voltages of the three-phase four-leg grid-forming power converter. Simulations results are also presented to verify the performance of the suggested control strategy

A Genome-Wide Study of Cytogenetic Changes in Colorectal Cancer Using SNP Microarrays: Opportunities for Future Personalized Treatment

In colorectal cancer (CRC), chromosomal instability (CIN) is typically studied using comparative-genomic hybridization (CGH) arrays. We studied paired (tumor and surrounding healthy) fresh frozen tissue from 86 CRC patients using Illumina's Infinium-based SNP array. This method allowed us to study CIN in CRC, with simultaneous analysis of copy number (CN) and B-allele frequency (BAF) - a representation of allelic composition. These data helped us to detect mono-allelic and bi-allelic amplifications/deletion, copy neutral loss of heterozygosity, and levels of mosaicism for mixed cell populations, some of which can not be assessed with other methods that do not measure BAF. We identified associations between CN abnormalities and different CRC phenotypes (histological diagnosis, location, tumor grade, stage, MSI and presence of lymph node metastasis). We showed commonalities between regions of CN change observed in CRC and the regions reported in previous studies of other solid cancers (e.g. amplifications of 20q, 13q, 8q, 5p and deletions of 18q, 17p and 8p). From Therapeutic Target Database, we identified relevant drugs, targeted to the genes located in these regions with CN changes, approved or in trials for other cancers and common diseases. These drugs may be considered for future therapeutic trials in CRC, based on personalized cytogenetic diagnosis. We also found many regions, harboring genes, which are not currently targeted by any relevant drugs that may be considered for future drug discovery studies. Our study shows the application of high density SNP arrays for cytogenetic study in CRC and its potential utility for personalized treatment

Five insights from the Global Burden of Disease Study 2019

The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 provides a rules-based synthesis of the available evidence on levels and trends in health outcomes, a diverse set of risk factors, and health system responses. GBD 2019 covered 204 countries and territories, as well as first administrative level disaggregations for 22 countries, from 1990 to 2019. Because GBD is highly standardised and comprehensive, spanning both fatal and non-fatal outcomes, and uses a mutually exclusive and collectively exhaustive list of hierarchical disease and injury causes, the study provides a powerful basis for detailed and broad insights on global health trends and emerging challenges. GBD 2019 incorporates data from 281 586 sources and provides more than 3.5 billion estimates of health outcome and health system measures of interest for global, national, and subnational policy dialogue. All GBD estimates are publicly available and adhere to the Guidelines on Accurate and Transparent Health Estimate Reporting. From this vast amount of information, five key insights that are important for health, social, and economic development strategies have been distilled. These insights are subject to the many limitations outlined in each of the component GBD capstone papers.Peer reviewe